Novel Therapies Surge Forward in Relapsed/Refractory Multiple Myeloma

Caroline Seymour
Published: Tuesday, Nov 26, 2019
Thomas G. Martin, MD, a clinical professor of medicine in the Adult Leukemia and Bone Marrow Transplantation Program at the University of California, San Francisco, Seattle Cancer Care Alliance

Thomas G. Martin, MD

Several novel agents are under investigation in relapsed/refractory multiple myeloma, including bispecific T-cell engagers (BiTEs), chimeric antigen receptor (CAR) T-cell therapies, and antibody-drug conjugates (ADCs), all of which have shown significant potency in heavily pretreated patient populations, explained Thomas G. Martin, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication